These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26150847)

  • 21. Clinical and procedural predictors and short-term survival of the patients with no reflow phenomenon after primary percutaneous coronary intervention.
    Ashraf T; Khan MN; Afaque SM; Aamir KF; Kumar M; Saghir T; Rasool SI; Rizvi SNH; Sial JA; Nadeem A; Khan AA; Karim M
    Int J Cardiol; 2019 Nov; 294():27-31. PubMed ID: 31387823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction.
    Zhou SS; Tian F; Chen YD; Wang J; Sun ZJ; Guo J; Jin QH
    J Geriatr Cardiol; 2015 Mar; 12(2):135-42. PubMed ID: 25870616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Wang Z; Ren L; Lei L; Ye H; Peng J
    Acta Cardiol; 2016 Apr; 71(2):241-6. PubMed ID: 27090048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Tasar O; Karabay AK; Oduncu V; Kirma C
    Coron Artery Dis; 2019 Jun; 30(4):270-276. PubMed ID: 31026233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Kurtul A; Yarlioglues M; Celik IE; Duran M; Elcik D; Kilic A; Oksuz F; Murat SN
    Coron Artery Dis; 2015 Dec; 26(8):706-12. PubMed ID: 26340546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relation of admission neutrophil/lymphocyte ratio to angiographic no-reflow phenomenon in patients with ST-elevated myocardial infarction undergoing primary coronary intervention].
    Niu X; Zhang Y; He S; Chen D; Yan D; Yao Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Jul; 35(7):856-60. PubMed ID: 25294082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil/Lymphocyte Ratio as a Predictor of In-Hospital Major Adverse Cardiac Events, New-Onset Atrial Fibrillation, and No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction.
    Wagdy S; Sobhy M; Loutfi M
    Clin Med Insights Cardiol; 2016; 10():19-22. PubMed ID: 26884687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction.
    Balta S; Celik T; Ozturk C; Kaya MG; Aparci M; Yildirim AO; Demir M; Kilic S; Aydin İ; Iyisoy A
    Am J Emerg Med; 2016 Aug; 34(8):1542-7. PubMed ID: 27238848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
    Kurtul A; Yarlioglues M; Murat SN; Ergun G; Duran M; Kasapkara HA; Demircelik MB; Cetin M; Ocek AH
    Am J Cardiol; 2014 Aug; 114(3):342-7. PubMed ID: 24948493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zhao Y; Yang J; Ji Y; Wang S; Wang T; Wang F; Tang J
    Heart Vessels; 2019 Oct; 34(10):1600-1607. PubMed ID: 30993442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of Mean Platelet Volume-to-Lymphocyte Ratio for Predicting Angiographic No-Reflow and Short-Term Prognosis After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction.
    Kurtul A; Acikgoz SK
    Am J Cardiol; 2017 Aug; 120(4):534-541. PubMed ID: 28633762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality.
    Choo EH; Kim PJ; Chang K; Ahn Y; Jeon DS; Lee JM; Kim DB; Her SH; Park CS; Kim HY; Yoo KD; Jeong MH; Seung KB
    Coron Artery Dis; 2014 Aug; 25(5):392-8. PubMed ID: 24625688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated neutrophil-to-lymphocyte ratio can predict procedural adverse events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Pinheiro Machado G; Araujo GN; Carpes CK; Lech MC; Mariani S; Valle FH; Bergoli LCC; Wainstein RV; Wainstein MV
    Coron Artery Dis; 2019 Jan; 30(1):20-25. PubMed ID: 30334819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The triglyceride-glucose index is associated with no-reflow phenomenon in STEMI patients with type 2 diabetes after percutaneous coronary intervention.
    Ma J; Wu P; Ma S; Ma X; Jin P; Jia S
    Front Cardiovasc Med; 2024; 11():1386318. PubMed ID: 39346096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Nomogram model for predicting the occurrence of no-reflow phenomenon after percutaneous coronary intervention using the lncRNA
    Hu CK; Cai RP; He L; He SR; Liao JY; Su Q
    J Thorac Dis; 2022 Jun; 14(6):2158-2168. PubMed ID: 35813727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
    Sen N; Afsar B; Ozcan F; Buyukkaya E; Isleyen A; Akcay AB; Yuzgecer H; Kurt M; Karakas MF; Basar N; Hajro E; Kanbay M
    Atherosclerosis; 2013 May; 228(1):203-10. PubMed ID: 23489347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.
    Topuz M; Oz F; Akkus O; Sen O; Topuz AN; Bulut A; Ozbicer S; Okar S; Koc M; Gur M
    Perfusion; 2017 Apr; 32(3):206-213. PubMed ID: 27770057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction.
    Schram HCF; Hemradj VV; Hermanides RS; Kedhi E; Ottervanger JP;
    Int J Cardiol; 2018 Aug; 265():12-17. PubMed ID: 29731349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.
    Acet H; Ertaş F; Akil MA; Bilik MZ; Aydin M; Polat N; Yildiz A
    Turk J Med Sci; 2016 Apr; 46(3):604-13. PubMed ID: 27513233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.